Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions
Yerly, S.; Günthard, H.F.; Fagard, C.; Joos, Béda.; Perneger, T.V.; Hirschel, B.; Perrin, L.
Aids 18(14): 1951-1953
2004
ISSN/ISBN: 0269-9370 PMID: 15353981 DOI: 10.1097/00002030-200409240-00011Document Number: 235584
In HIV-1-infected patients with long-term undetectable viraemia on highly active antiretroviral treatment (HAART), we found that pre-HAART plasma viraemia and the baseline proviral DNA level were significantly associated with the viraemia setpoint during scheduled treatment interruptions. In long-term treated patients, pre-HAART viraemia may not be available, and in these circumstances proviral DNA, measured at the time of scheduled treatment interruption, can help to identify patients likely to reach a low viraemia setpoint after treatment interruption.